

Henry Ford Health

## Henry Ford Health Scholarly Commons

---

Orthopedics Articles

Orthopedics / Bone and Joint Center

---

1-1-2023

### **Efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute pain after orthopedic trauma: a practice management guideline from the Eastern Association for the Surgery of Trauma and the Orthopedic Trauma Association**

Patrick B. Murphy

George Kasotakis

Elliott R. Haut

Anna Miller

Edward Harvey

*See next page for additional authors*

Follow this and additional works at: [https://scholarlycommons.henryford.com/orthopaedics\\_articles](https://scholarlycommons.henryford.com/orthopaedics_articles)





---

---

**Authors**

Patrick B. Murphy, George Kasotakis, Elliott R. Haut, Anna Miller, Edward Harvey, Eric Hasenboehler, Thomas Higgins, Joseph Hoegler, Hassan Mir, Sarah Cantrell, William T. Obremskey, Meghan Wally, Basem Attum, Rachel Seymour, Nimit Patel, William Ricci, Jennifer J. Freeman, Krista L. Haines, Brian K. Yorkgitis, and Brandy B. Padilla-Jones

# Efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute pain after orthopedic trauma: a practice management guideline from the Eastern Association for the Surgery of Trauma and the Orthopedic Trauma Association

Patrick B Murphy <sup>1</sup>, George Kasotakis <sup>2</sup>, Elliott R Haut <sup>3</sup>, Anna Miller,<sup>4</sup> Edward Harvey,<sup>5</sup> Eric Hasenboehler,<sup>6</sup> Thomas Higgins,<sup>7</sup> Joseph Hoegler,<sup>8</sup> Hassan Mir,<sup>9</sup> Sarah Cantrell,<sup>10</sup> William T Obrebsky,<sup>11</sup> Meghan Wally,<sup>12</sup> Basem Attum,<sup>13</sup> Rachel Seymour,<sup>12</sup> Nimit Patel,<sup>14</sup> William Ricci,<sup>15</sup> Jennifer J Freeman <sup>16</sup>, Krista L Haines,<sup>10</sup> Brian K Yorkgitis,<sup>17</sup> Brandy B Padilla-Jones<sup>18</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/tsaco-2022-001056>).

For numbered affiliations see end of article.

## Correspondence to

Dr Patrick B Murphy;  
[pbatesmurphy@gmail.com](mailto:pbatesmurphy@gmail.com)

Received 7 November 2022  
Accepted 9 January 2023

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Murphy PB, Kasotakis G, Haut ER, et al. *Trauma Surg Acute Care Open* 2023;**8**:e001056.

## ABSTRACT

**Objectives** Fracture is a common injury after a traumatic event. The efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) to treat acute pain related to fractures is not well established.

**Methods** Clinically relevant questions were determined regarding NSAID use in the setting of trauma-induced fractures with clearly defined patient populations, interventions, comparisons and appropriately selected outcomes (PICO). These questions centered around efficacy (pain control, reduction in opioid use) and safety (non-union, kidney injury). A systematic review including literature search and meta-analysis was performed, and the quality of evidence was graded per the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. The working group reached consensus on the final evidence-based recommendations.

**Results** A total of 19 studies were identified for analysis. Not all outcomes identified as critically important were reported in all studies, and the outcome of pain control was too heterogenous to perform a meta-analysis. Nine studies reported on non-union (three randomized control trials), six of which reported no association with NSAIDs. The overall incidence of non-union in patients receiving NSAIDs compared with patients not receiving NSAIDs was 2.99% and 2.19% ( $p=0.04$ ), respectively. Of studies reporting on pain control and reduction of opioids, the use of NSAIDs reduced pain and the need for opioids after traumatic fracture. One study reported on the outcome of acute kidney injury and found no association with NSAID use.

**Conclusions** In patients with traumatic fractures, NSAIDs appear to reduce post-trauma pain, reduce the need for opioids and have a small effect on non-union. We conditionally recommend the use of NSAIDs in patients suffering from traumatic fractures as the benefit appears to outweigh the small potential risks.

## INTRODUCTION

Opioids have traditionally been used for analgesia after trauma; however, misuse and abuse of opioids have reached epidemic proportions.<sup>1</sup> In the

### WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ The use of non-steroidal anti-inflammatory drugs (NSAIDs) for analgesia after traumatic fracture is inconsistent and controversial due to uncertainty about the balance of harm (non-union) and benefit (analgesia and opioid reduction).

### WHAT THIS STUDY ADDS

⇒ NSAIDs have a clear analgesic and opioid reduction effect with a minimal increase in non-union when prescribed to patients with acute traumatic fractures.

### HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The benefits of NSAIDs in the treatment of acute traumatic fracture outweigh the potential harms.

last three decades, drug overdoses, largely due to opioids, have tripled.<sup>2</sup> This public health crisis has led providers to consider alternative pharmaceuticals to control pain after trauma. Therefore, there is an upsurge in the interest of non-steroidal anti-inflammatories (NSAIDs) for acute pain control, particularly in trauma patients. However, the safety and efficacy of NSAIDs for acute pain control after fracture has not been well established, and debate remains about potential risks.

Traditionally, the most concerning adverse event related to NSAID use after orthopedic trauma is fracture non-union. Unfortunately, numerous attempts to study and quantify the relationship have led to conflicting results.<sup>3–23</sup> Furthermore, alternative treatments to NSAIDs, including opioids, have demonstrated similar associations to non-union.<sup>18</sup> A number of meta-analyses and systematic reviews have been performed in the non-trauma population with mixed results.<sup>24–26</sup> It remains unclear whether increased pain medication (NSAIDs or opioids) directly increases rates of non-union or instead, the

pain secondary to non-union increases the use of these medications. The risks and benefits of using NSAIDs for managing acute pain in patients with traumatic fractures remains unclear, and practices across North America vary greatly. The current Orthopedic Trauma Association (OTA) and American Academy of Orthopaedic Surgeons guidelines focus on acute musculoskeletal injuries and only explore fracture healing and do not discuss other potential harms such as acute kidney injury.<sup>27,28</sup>

We performed a systematic review and meta-analysis to develop evidenced-based recommendations to determine whether NSAIDs were safe and effective in patients with traumatic fractures, following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology<sup>29</sup> on behalf of Eastern Association for The Surgery of Trauma (EAST) and the OTA.

## OBJECTIVES

A working group was formed under the EAST Guidelines Committee in collaboration with the Orthopedic Trauma Association to formulate an evidence-based guideline on NSAID use after orthopedic trauma.<sup>30</sup> The GRADE methodology was used.<sup>31</sup>

## METHODS

Population, intervention and comparator (PIC) questions were generated a priori to the systematic literature review. Pertinent outcomes (O) were identified by the working group and then independently each member voted on outcomes using a scale of 1 to 9. Outcomes that received a rounded average score of 7 to 9 were deemed critical outcomes, those receiving a score of 4 to 6 were considered important but not critical and those receiving a score of 1 to 3 were considered of limited importance. Only critically important outcomes (7 to 9 rating) were considered in decision making for generating the final recommendations.

PICO 1: should NSAIDs be used in analgesic regimens for adult patients ( $\geq 18$  years old) with traumatic fracture versus routine analgesic regimens that do not include NSAIDs to improve analgesia and reduce oral morphine equivalents (OMEs), without increases in non-union and acute kidney injury rates?

PICO 2: should ketorolac be used in analgesic regimens for adult patients ( $\geq 18$  years old) with traumatic fracture versus routine analgesic regimens that do not include ketorolac to improve analgesia and reduce OMEs, without increasing non-union rates?

PICO 3: should selective NSAIDs (COX-2 inhibitors) be used in analgesic regimens for adult patients ( $\geq 18$  years old) with traumatic fracture versus routine analgesic regimens that include non-selective NSAIDs to improve analgesia and reduce OMEs, without increasing non-union rates?

Acute kidney injury was deemed critical as an outcome for PICO 1 but not for PICO 2 and PICO 3 (score of 6).

COX-2 inhibitors included the coxib medications and meloxicam.

## Identification of references

Our project was registered with the PROSPERO registry of systematic reviews and meta-analyses (CRD42020167575). Published literature was searched through MEDLINE (via Ovid), Embase (via Elsevier), Cochrane Central Register of Controlled Trials (via Wiley) and Web of Science (via Clarivate) databases by a professional librarian (SC) on March 18, 2020 and updated on February 25, 2021. The search used a combination of database-specific subject headings and keywords for the following concepts: NSAIDs, Opioids, Orthopedic Procedures, Fracture in

various iterations and combinations. Results were limited to the English language. The full search strategy is available in online supplemental file 1.

Studies that included adult ( $\geq 18$  years old) trauma patients with any fracture were eligible for inclusion. Case reports, case series, commentaries, reviews, editorials and animal studies were excluded. For a study to be included in our final analysis, a clear comparison between patients receiving NSAIDs and control patients had to be present, as well as at least one of the critical outcomes reported. Studies in which NSAIDs were part of a multimodal approach to pain control compared with no multimodal pain control were excluded as the impact of NSAIDs was unable to be determined. Specifically, studies that did not report the specific impact of NSAIDs independent of other medications were not included.

Titles and abstracts were screened independently by two team members for inclusion in our meta-analysis. Conflicts were blindly adjudicated by a third member. Full-text review was also performed by two team members working independently, with conflicts adjudicated by a blinded third member. Included articles had their reference lists reviewed by two team members for identification of potential additional articles. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for our systematic review is depicted in figure 1.


## Data extraction and methodology

Data extraction from each included study was performed using a standardized data collection sheet and was performed in duplicate. Discrepancies were adjudicated by a third author. Data extracted included authors, journal, publication year, study design, number of patients, type of fracture(s), indication for NSAIDs (heterotopic ossification prevention vs pain control), type of NSAID(s) used, dose and duration (if available), number of patients in each experimental and control arms, as well as the critical outcomes previously listed. The definition of non-union in the literature is inconsistent and varied widely between studies. Due to the variability, the study definition was used and captured.

Meta-analysis was performed in Review Manager (RevMan V.5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) with random-effects modeling to generate forest plots. For dichotomous outcomes, the Mantel-Haenszel random effects model was used to calculate a pooled event rate and OR. For continuous outcomes, inverse variance was used to calculate a mean difference between interventions. Treatment effects were calculated with each study weight being proportional to the number of subjects it contributed to each outcome. Heterogeneity was calculated and quantified with  $I^2$ . High heterogeneity was considered present for  $I^2$  values  $>75\%$ , moderate for  $I^2$  values of 50% to 74% and low if  $I^2 <50\%$ .

Publication bias was evaluated using the Egger test, and the GRADE framework was applied to all quantified outcomes for assessment of bias, publication bias, inconsistency, imprecision and indirectness. Evidence profiles were created for each PICO using GRADEpro GDT software (GRADEpro Guideline Development Tool, McMaster University, 2015).

All committee members voted initially independently taking into consideration the quality of evidence, relationship of benefits and harms, perceived patient values and preferences, and resource utilization. Our PICO questions and analysis results (forest plots, GradePRO table, risk of bias assessment and summary of study types) were submitted to two external



**Figure 1** PRISMA flow diagram. PRISMA, preferred reporting items for systematic reviews and meta-analyses.

GRADE experts for blind review. No Institutional ethics was not necessary as we did not examine any individual patient data.

## RESULTS

Most studies were based in the USA, and 10 were prospective randomized control trials. Three included studies investigated the use of indomethacin for prevention of HO, as opposed to for pain control, and reported on outcomes identified as critically important, including non-union (table 1). Two studies<sup>12 18</sup> used the same cohort of patients, and only Zura *et al*<sup>12</sup> was used for quantitative synthesis.

### PICO 1

Should NSAIDs be used in analgesic regimens for adult patients ( $\geq 18$  years old) with traumatic fracture versus routine analgesic regimens that do not include NSAIDs to improve analgesia and reduce OMEs, without increases in non-union and acute kidney injury rates?

#### Non-union

##### Qualitative synthesis

Nine studies<sup>4 6 12-15 18 21 22</sup> investigated the impact of NSAIDs on non-union (table 2). In general, non-union was not objectively defined or defined as persistent fracture at variable time-points. Three studies<sup>13-15</sup> were randomized control trials, two<sup>13 15</sup> of which investigated the use of indomethacin for the prevention of HO and reported on non-union. Most studies ( $n=6$ ) found no relationship between NSAIDs and non-union, and of the three

studies<sup>6 13 15</sup> demonstrating an effect, two<sup>13 15</sup> were studies on the long-term (6 weeks) use of indomethacin for the prevention of HO.

McDonald *et al*<sup>14</sup> randomized 128 patients undergoing fixation or ankle fractures to receive 30 mg intravenous ketorolac intraoperatively and 20 tablets of 10 mg ketorolac postoperatively or usual care. Additionally, both groups were prescribed 81 mg of ASA for deep vein thrombosis prevention. At 12 weeks, there was no difference in experimental or control groups in non-union (17% vs 23% respectively,  $p=0.43$ ). Buchheit *et al*<sup>18</sup> and Zura *et al*<sup>12</sup> used patient-level health claims data in North Carolina and evaluated 309 330 fractures and the impact of numerous medications, including NSAIDs, on fracture healing. Acute use of NSAIDs ( $<30$  days) was not associated with non-union in any of the fractures studied (18 bones), OR 0.98 (95% CI 0.89 to 1.07). Patients chronically using NSAIDs (prior to fracture) did have increased non-union OR 1.22 (95% CI 1.15 to 1.43). Causality was not established. Other medications investigated did have an association with non-union including acute opioid use (OR 1.47, 95% CI 1.40 to 1.54) and anticonvulsants (OR 1.2, 95% CI (1.16 to 1.29)).

Moed *et al*<sup>21</sup> investigated indomethacin for HO. In their retrospective cohort study, the authors compared patients with acetabular fractures who received 6 weeks of indomethacin compared with patients who did not receive indomethacin. No patients in either group experienced non-union. Hunter *et al*<sup>22</sup> performed a retrospective chart review comparing patients receiving ASA for DVT prevention to patients who did not receive ASA. ASA was

**Table 1** Studies reporting on efficacy and safety of NSAIDs after orthopedic fracture in adult patients

Author (ID)	State or country	Year	Study design	Study size	Patient population (types of fractures and surgery)	NSAIDs used	Duration (time or doses)	Indication for NSAIDs	Outcomes measured
Mehta <sup>23</sup>	India	1986	Randomized control trial	254	Long bone fractures who underwent fixation	Dipyron (500 mg) or ASA (500 mg)	One dose	Pain control	Pain
Hunter <sup>22</sup>	USA	2020	Retrospective cohort	502	Malleolar ankle fractures who underwent fixation	ASA (325 mg)	Daily for 6 to 8 weeks	DVT prophylaxis	Non-union
Moed <sup>21</sup>	USA	1984	Retrospective cohort	35	Acetabular fractures who underwent fixation	Indomethacin (25 mg)	TID for 6 weeks	Prevent HO	Non-union
Jeffcoach <sup>19</sup>	USA	2014	Retrospective cohort	193	Femur, tibia and/or humeral fractures	8 different NSAIDs	IQR 1.0 to 8.5 doses	Pain control	Non-union
Buchheit <sup>18</sup>	USA	2018	Retrospective cohort	309 330	Bone fracture in year 2011	Any NSAID, dose not reported	Acute (<30 days) Chronic (≥30 days)	Not reported	Non-union
Adolphson <sup>17</sup>	Sweden	1993	Randomized control trial	33	Colles' fracture in postmenopausal women	Piroxicam (20 mg)	Daily for 8 weeks	Reduction in osteopenia	Pain
Weisz <sup>16</sup>	USA	2021	Randomized control trial	99	Fracture of ribs, face, extremities or pelvis	IV Ibuprofen (800 mg)	Eight doses over 2 days	Pain	Pain, OMEs
Sagi <sup>15</sup>	USA	2014	Randomized control trial	98	Acetabular fractures who underwent fixation	Indomethacin (75 mg)	Daily for 3 days, 1 week or 6 weeks	Prevent HO	Non-union
McDonald <sup>14</sup>	USA	2019	Randomized control trial	128	Ankle fractures who underwent operative treatment	Ketorolac 30 mg IV intra-op+20 tabs Ketorolac 10 mg	7 days	Pain	Pain, OMEs, non-union
Burd <sup>13</sup>	USA	2003	Randomized control trial	112	Acetabular fractures who underwent fixation	Indomethacin (25 mg)	Three times a day for 6 weeks	Prevent HO	Non-union
Zura <sup>12</sup>	USA	2016	Retrospective cohort	309 330	Bone fracture in year 2011	Any NSAID, dose not reported	Not reported	Not reported	Non-union
Ortiz <sup>10</sup>	Mexico	2010	Randomized control trial	49	Ankle fracture and pain >5/10	Ketorolac (10 mg) Diclofenac (70 mg) Etoricoxib (60 mg)	Two doses	Pain	Pain
Bayouth <sup>9</sup>	USA	2013	Retrospective cohort (matched)	42	Rib fractures	IV Ibuprofen	600 to 800 mg every 6 hours	Pain	Pain, OMEs
Eftekharian <sup>8</sup>	Iran	2017	Randomized clinical trial	50	Mandibular fracture	Ketorolac	Single postoperative dose	Pain	Pain
Xu <sup>7</sup>	USA	2016	Randomized clinical trial	63	Femoral or tibiofibular fractures	Ketorolac	In postoperative analgesia pump	Pain	Pain, OMEs
Tucker <sup>6</sup>	USA	2020	Retrospective cohort	17 689	Operatively treated long-bone fractures	NSAID No NSAID	Up to 90 days	Not reported	Non-union
Aliuskevicius <sup>3</sup>	Denmark	2021	Randomized control trial	96	Non-surgically treated Colles' fractures	Ibuprofen	3 days or 7 days	Pain control	Pain
Haines <sup>5</sup>	USA	2020	Retrospective cohort	190 057	≥65 year old who underwent hip or femur fixation for fracture	Any NSAID	Not reported	Not reported	OMEs, acute kidney injury
George <sup>4</sup>	USA	2020	Retrospective cohort	339 864	Single long-bone fracture or commonly paired long-bone fractures	Any NSAID, dose not reported; COX-2 or non-selective	Not reported	Not reported	Non-union

†Institution specific.

‡For both groups combined.

ASA, aspirin; DVT, deep vein thrombosis; HO, heterotopic ossification; NSAIDs, non-steroidal anti-inflammatory drugs; OME, oral morphine equivalents.

prescribed for 6 to 8 weeks after ankle fracture. Compared with patients without ASA use, there was no difference in non-union (3.1% vs 1%,  $p=0.21$ ). Finally, George *et al*<sup>4</sup> used claims data in Texas over 15 years to determine the association of NSAIDs (selective and non-selective) and opioids on non-union after any traumatic fracture. Any NSAID use had a higher incidence of non-union (1.2% vs 0.8%); however, this difference disappeared when only non-selective NSAIDs were considered (OR 1.08 95%CI 0.96 to 1.20). Notably, opioid prescription was associated with non-union as well (1.3% vs 0.5%, OR 1.53 (95%CI 1.43 to 1.64)).

Three studies concluded there was an association between NSAID use and non-union. Tucker *et al*<sup>6</sup> in a retrospective study of an insurance database found any use of postfixation NSAIDs (at any direction <90 days) was associated with non-union for subtrochanteric femur fractures (OR1.5, 95% 1.24 to 1.84), tibial shaft fracture (OR 1.42, 95% CI 1.19 to 1.69) and humeral shaft fracture (OR 1.2, 95% CI 1.0 to 1.46) as was tobacco use, peripheral vascular disease, obesity and infection. Studies from

Burd *et al*<sup>13</sup> and Sagi *et al*<sup>15</sup> randomized patients with acetabular fractures to receive indomethacin for up to 6 weeks to prevent HO. Unlike Burd *et al*, Sagi included patients randomized to 3 days and 1 week as well as the longer 6 week duration. Both studies demonstrated a high proportion of patients experiencing non-union at 6 weeks (15% to 29%). Indomethacin for 3 to 7 days had no impact on non-union rates compared with placebo. Sagi *et al* had significant loss to follow-up but loss to follow-up was not reported by Burd *et al*.

Several studies investigated other factors that may be associated with non-union including tobacco use, obesity and other medications such as opioids, all of which demonstrated an association.<sup>12 18</sup>

### Quantitative synthesis

Eight studies<sup>4 6 12 14 15 18 21 22</sup> were included in the primary analysis (figure 2). A total of 51 687 patients received NSAIDs, while 581 702 did not. The non-union rate was 2.99% in the NSAID

**Table 2** PICO 1.1 – impact of NSAIDs on non-union

Author	Non-union definition	Groups	N	Male, n (%)	Age, year, mean (SD)	Non-union, n (%)	Lost to follow-up, n (%)	Study conclusions
Hunter <sup>22</sup>	Persistent fracture at 24 weeks	ASA No ASA	152 354	66 (43) 163 (46)	44 (NA) 42 (NA)	3 (3) 2 (1)	54 (34) 154 (41)	ASA for 6 to 8 weeks postoperatively does not influence time to union
Moed <sup>21</sup>	Not defined	Indomethacin No indomethacin	16 19	NA NA	32 (NA) 32 (NA)	0 (0) 0 (0)	NA NA	No problems with fracture healing noted
Buchheit <sup>18</sup>	Not defined	NSAID Acute NSAID Chronic NSAID No NSAID	2525 2180 527 306 579	NA NA NA NA	NA NA NA NA	227 (8.3) 183 (8.4) 44 (7.7) 15 022 (4.9)	0% at 12 months (only complete cases included)	Numerous medications are associated with non-union including antibiotics, anticoagulants, bisphosphonates, opioids and NSAIDs. Non-union depends on fracture location.
Sagi <sup>15</sup>	Lack of bridging callus and visible fracture line	Indomethacin 3 days 1 week 6 weeks Placebo	72 24 25 23 26	(70%) (76%) (80%) (67%)	41 (NA) 34 (NA) 42 (NA) 46 (NA)	18 (25) 6 (35) 4 (24) 8 (62) 4 (19)	29% 32% 43% 19%	Indomethacin is not indicated in the prevention of HO after acetabular fracture. One week on indomethacin may be safe to prevent HO without an increase in non-union.
McDonald <sup>14</sup>	Clinical healing (walking) and radiographic healing (blinded review)	Ketorolac No ketorolac	64 64	23 (36) 30 (57)	48 (15) 46 (17)	0 (0) 0 (0)	One, unclear which group	Ketorolac reduced post-op pain and OMEs but unclear effect on healing due to study power.
Burd <sup>13</sup>	Not defined	Indomethacin No indomethacin	38 74	NA NA	40 (NA) 38 (NA)	11 (29) 5 (7)	NA NA	Avoid NSAIDs for analgesia or anti-inflammatory purposes during healing of fractures.
Zura <sup>12</sup>	Coded non-union or code for electrical bone stimulation	NSAID No NSAID	23 847 285 384	NA NA	NA NA	661 (2.8) 14 588 (5.1)	NA NA	No impact of NSAIDs on healing; fracture healing is a diverse process and non-union can result from many risk factors.
Tucker <sup>6</sup>	Coded non-union	NSAID No NSAID	15 119 2 570	NA NA	NA NA	1 179 (7.8) 392 (10.4)	NA NA	Exposure to NSAIDs at any point during the 90-day postoperative period was associated with fracture non-union (no opioid adjustment)
George <sup>4</sup>	Non-union diagnosis code or a procedure to treat non-union	NSAID No NSAID	25 001 279 720	11 229 (45) 103 003 (37)	49 (17) 60 (19)	456 (1.8) 4 118 (1.5)	All had 1-year follow-up	Filling a prescription for a non-selective NSAID after fracture was not associated with an increased risk of non-union in the subsequent year. Both COX-2-inhibitor and opioid prescription fills after fracture were associated with a greater risk of non-union.

group compared with 2.18% in the no NSAID group (OR 1.45, 95%CI 1.04 to 2.01). Heterogeneity was very high ( $I^2=93%$ ) and was statistically significant ( $p<0.03$ ). The high statistical heterogeneity may be due to differences in the fracture type, NSAID type and duration of use, or an unmeasured confounder.


**Reduction of morphine equivalents**

*Qualitative synthesis*

Five studies<sup>5,7,9,14,16</sup> examined the impact of NSAIDs on morphine equivalents (table 3). Weisz *et al*<sup>16</sup> randomized fracture patients to receiving ibuprofen or placebo and measured OMEs at 48

hours. Patients receiving Ibuprofen had significantly lower OMEs compared with patients receiving placebo (76 mg vs 97 mg,  $p=0.017$ ).

Xu *et al*<sup>7</sup> randomized patients undergoing orthopedic surgery from lower limb fractures to receiving a ketorolac pump or a non-ketorolac pain pump. Sufentanel dose at 48 hours was significantly less (194 vs 130 OME,  $p<0.05$  (actual p value not reported)) for those patients receiving ketorolac. Bayouth *et al*<sup>9</sup> performed a retrospective chart review of patients with rib fractures and compared patients receiving ibuprofen to patients receiving routine care. At 7 days, OMEs



**Figure 2** Odds of non-union in patients with traumatic fractures receiving NSAIDs compared with patients not receiving NSAIDs. NSAIDs, non-steroidal anti-inflammatories.

**Table 3** PICO 1.2 impact of NSAIDs on morphine equivalents

Author	Outcome definition	Groups	N	Male, n (%)	Age, y, mean (SD)	OME/MME	Study conclusions
Weisz <sup>16</sup>	OME at 48 hours	Ibuprofen Placebo	54 44	38 (72) 34 (77)	42 (16) 41 (16)	23 (18) 27 (16)	Ibuprofen significantly reduces opioids after traumatic fractures
McDonald <sup>14</sup>	OME at 7 days	Ketorolac No ketorolac	64 64	23 (36%) 30 (57%)	48 (15) 46 (17)	105 (89) 145 (104)	Decreased use of opioid medications
Xu <sup>7</sup>	OME at 48 hours	Ketorolac No ketorolac	31 32	16(51) 17 (53)	50 (11) 49 (12)	130 (48 hours) 194 (48 hours)	Significantly less opioid use in ketorolac group
Bayouth <sup>9</sup>	OME at 7 days	Ibuprofen No ibuprofen	21 21	13 (62) 17 (81)	52 (14) 53 (16)	83 (54) 170 (115)	Significantly less opioid use in ibuprofen group
Haines <sup>5</sup>	OME during hospital day	NSAID No NSAID	21 367 168 690	NR NR	83 84	12 (13) 11 (13)	Significantly less opioid use in the NSAID group

MME, Morphine Milligram Equivalents; NSAIDs, non-steroidal anti-inflammatory drugs; OME, oral morphine equivalent.

were significantly less in the ibuprofen group (83 mg vs 170 mg,  $p=0.004$ ).

McDonald *et al*<sup>14</sup> randomized 128 patients undergoing fixation or ankle fractures to receive 30mg intravenous ketorolac intraoperatively and 20 tablets of 10mg ketorolac postoperatively or usual care. Significantly fewer opioids (40 OMEs fewer,  $p=0.037$ ) were used in the ketorolac group. Haines *et al*<sup>5</sup> retrospectively analyzed a billing database of older adult trauma patients with hip fractures. Patients receiving NSAIDs (any type) had similar opioid use (milligram morphine equivalence, OME) during their hospital stay (11.43 v 12.01 mg,  $p=0.05$ ), and this was significantly reduced in the NSAID group on multivariate regression ( $-0.23$ , 95% CI  $-0.41$  to  $-0.06$ ).

### Quantitative synthesis

Due to differences in reporting of OMEs only two studies<sup>9 14</sup> could be included for a quantitative synthesis for OMEs at 7 days (figure 3). There is a significant reduction in OMEs at 7 days in patients receiving NSAIDs ( $-56$  mg, 95% CI  $-88$  to  $-24$ ) with moderate heterogeneity ( $I^2=48\%$ ,  $p=0.17$ ).

### Analgesia

#### Qualitative synthesis

Mehta *et al*<sup>23</sup> randomized patients with uncomplicated long-bone fractures to receive dipyron or aspirin or placebo. Mean pain relief scores at 6 hours were lowest in dipyron (3.2) and aspirin (2), and pain relief was worst for placebo (1.3) with a significant difference ( $p<0.001$ ), table 4.

Adolphson *et al*<sup>17</sup> randomized postmenopausal patients to piroxicam or placebo after suffering from a Colles' fracture. Pain at 10 days on a 11-point visual analog scale was significantly lower in the piroxicam group (2.1) compared with placebo (3.1,  $p<0.05$  (actual  $p$  value not reported)). Weisz *et al*<sup>16</sup> randomized fracture patients to receiving ibuprofen or placebo and measured pain intensity difference between groups. The patients receiving ibuprofen had significantly less pain in

the first 8 hours of treatment (2.5/10 in the first 8 hours and 1.1/10 for ibuprofen group,  $p=0.013$ ). Xu *et al*<sup>7</sup> randomized patients undergoing orthopedic surgery from lower limb fractures to receiving a ketorolac pump or a non-ketorolac pain pump. There was no difference in visual analog pain scores at any time point up to 48 hours. Eftekharian *et al*<sup>8</sup> randomized patients with mandible fractures to receive a single dose of 30mg ketorolac or placebo in the postanesthesia unit at the onset of pain. There was no difference in pain intensity up to 4 hours of time.

Bayouth *et al*<sup>9</sup> performed a retrospective chart review of patients with rib fractures and compared patients receiving ibuprofen to patients receiving routine care. Mean highest daily pain scores during the first 7 days of hospitalization was significantly lower in patients receiving ibuprofen (7v. 8,  $p<0.04$ ). Similarly, mean lowest pain score was also significantly lower in the treatment group (3 vs 5,  $p<0.001$ ).


Aliuskevicius *et al*<sup>3</sup> randomized patients with Colles' fractures who did not undergo surgery to receive placebo, ibuprofen (3 days) or ibuprofen (7 days). The ibuprofen groups had significantly less pain in the first 7 days after fracture but no difference after 7 days.

### Quantitative synthesis

Due to difference in outcome definition and variable timing of pain scores a meta-analysis was not possible.

### Acute kidney injury

Only a single study reported on acute kidney injury. Haines *et al*<sup>5</sup> retrospectively analyzed a billing database of older adult trauma patients with hip fractures. There were similar rates of renal failure at baseline between the two groups (NSAID: 14% compared with no NSAIDs: 19%). There was no difference in new onset renal failure between groups (12% in no NSAIDs compared with 6% in NSAID group).



**Figure 3** Oral morphine equivalents in patients with traumatic fractures receiving NSAIDs compared with patients not receiving NSAIDs. NSAIDs, non-steroidal anti-inflammatories.



**Table 4** PICO 1.3 impact of NSAIDs on pain

Author	Outcome definition	Groups	N	Male, n (%)	Age, years, mean (SD)	Pain outcome	Study conclusions
Mehta <sup>23</sup>	Pain relief score (mean) at 6 hours	Dipyrone	91	74 (81)	31 (1)	3	Clear analgesic effect of single dose of dipyrone compared with ASA and placebo; ASA had worse side effect profile (16% abdominal discomfort).
		ASA	93	65 (70)	30 (1)	2	
		Placebo	70	54 (77)	31 (1)	1.3	
Adolphson <sup>17</sup>	Pain (VAS) at 10d, 4, 8 and 12 weeks	Piroxicam	14	0 (0)	NA	2.1 (at 10 days)	Significantly less pain in the Piroxicam group.
		Placebo	19	0 (0)	NA	3.2 (at 10 days)	
Weisz <sup>16</sup>	Mean pain intensity difference	Ibuprofen	54	38 (72)	42 (16)	1.1 (8 hours)	Ibuprofen significantly reduces pain after traumatic fractures.
		Placebo	44	34 (77)	41 (16)	2.5 (8 hours)	
McDonald <sup>14</sup>	Pain on each postoperative day	Ketorolac	64	23 (36)	48 (15)	30 (7 days)	Ketorolac reduced pain in first 3 days postoperatively.
		No ketorolac	64	30 (57)	46 (17)	30 (7 days)	
Xu <sup>7</sup>	Pain (VAS) at 48 hours	Ketorolac	31	16(51)	50 (11)	2 (48 hours)	No difference in pain control between ketorolac and no ketorolac groups when used in a postoperative pump.
		No ketorolac	32	17 (53)	49 (12)	2 (48 hours)	
Eftekharian <sup>8</sup>	Pain (VAS) at 4 hours	Ketorolac	25	15 (6)	30 (8)	1.08 (4 hours)	Single-dose ketorolac had limited efficacy on postoperative pain.
		Placebo	25	15 (6)	26 (8)	1.04 (4 hours)	
Bayouth <sup>9</sup>	Pain scores during first 7 days	Ibuprofen	21	13 (62)	52 (14)	7 (mean highest)	Significantly less pain during the 7 days post-trauma in the ibuprofen group.
		No Ibuprofen	21	17 (81)	53 (16)	8 (mean highest)	
Aliuskevicius <sup>3</sup>	Pain (VAS) during first 2 weeks	Ibuprofen 3 days	24	8 (33)	61 (8)	3 (day 4)	Significantly less pain in the first 7 days post-trauma in the 3 and 7 days ibuprofen groups.
		Ibuprofen 7 days	26	7 (26)	63 (11)	2.5 (day 4)	
		Placebo	30	8 (27)	63 (9)	4 (day 4)	

ASA, aspirin; d, day; NSAID, non-steroidal anti-inflammatory drugs; VAS, visual analog score.

### PICO 1 recommendation

We conditionally recommend NSAIDs to be used in analgesic regimens for adult patients ( $\geq 18$  years old) with traumatic fracture. Despite the low overall quality of evidence, most studies showed no association between NSAIDs on non-union. The larger, better controlled studies demonstrated no increased risk of non-union compared with other, commonly prescribed analgesics, including opioids. There was a clear impact on reduction of acute pain and use of opioid analgesia. Eight authors voted for a strong recommendation and 11 authors voted for conditional recommendation.

### PICO 2

Should ketorolac be used in analgesic regimens for adult patients ( $\geq 18$  years old) with traumatic fracture versus routine analgesic regimens that do not include ketorolac to improve analgesia and reduce OMEs, without increasing non-union rates?

### Qualitative synthesis

Three studies compared ketorolac use to no ketorolac use in patients with traumatic fractures (table 5). McDonald *et al*<sup>14</sup> randomized 128 patients undergoing fixation or ankle fractures to receive 30 mg intravenous ketorolac intraoperatively and 20

**Table 5** PICO 2 – summary of all outcomes

Author	Outcome definition	Groups	N	Male, n (%)	Age, year, mean (SD)	Outcome	Study conclusions
Non-union							
McDonald <sup>14</sup>	Clinical healing (walking) and radiographic healing (blinded review)	Ketorolac	64	23 (36)	48 (15)	0 (0)	Ketorolac reduced post-op pain and OMEs but unclear effect on healing due to study power.
		No ketorolac	64	30 (57)	46 (17)	0 (0)	
Morphine equivalents							
McDonald <sup>14</sup>	OME at 7 days	Ketorolac	64	23 (36)	48 (15)	105 (89)	Decreased use of opioid medications.
		No ketorolac	64	30 (57)	46 (17)	145 (104)	
Xu <sup>7</sup>	OME at 48 hours	Ketorolac	31	16(51)	50 (11)	130 (48 hours)	Significantly less opioid use in ketorolac group.
		No ketorolac	32	17 (53)	49 (12)	194 (48 hours)	
Pain							
Xu <sup>7</sup>	Pain (VAS) at 48 hours	Ketorolac	31	16(51)	50 (11)	2 (48 hours)	No difference in pain control between ketorolac and no ketorolac groups.
		No ketorolac	32	17 (53)	49 (12)	2 (48 hours)	
McDonald <sup>14</sup>	Pain on each postoperative day	Ketorolac	64	23 (36)	48 (15)	30 (7 days)	Ketorolac reduced pain in first 3 days postoperatively.
		No ketorolac	64	30 (57)	46 (17)	30 (7 days)	
Eftekharian <sup>8</sup>	Pain (VAS) at 4 hours	Ketorolac	25	15 (60)	30 (8)	1 (4 hours)	Single dose ketorolac was effective in the management of mild to moderate acute postoperative pain.
		Placebo	25	15 (60)	26 (8)	1 (hours)	

MME, morphine milligram equivalents; OME, oral morphine equivalent; VAS, visual analog scale.

tablets of 10 mg ketorolac postoperatively. Additionally, both groups were prescribed 81 mg of ASA for deep vein thrombosis prevention. Opioid consumption was lower in patients randomized to receive ketorolac (21 OMEs compared with 29 OMEs,  $p=0.04$ ). Like the reduction in OMEs, pain scores were lower on postoperative days 1 to 3 in the patients receiving ketorolac. Finally, there was no difference in the proportion of patients with complete union (83% in ketorolac group compared with 77% in control group) at 12 weeks.

Xu *et al*<sup>7</sup> randomized 63 patients to receive a post-operative pump containing ketorolac+sufentanil or sufentanil alone. There was no significant difference in pain at 48 hours but significantly less sufentanil was used in the group randomized to receive ketorolac.

Eftekharian *et al*<sup>8</sup> randomized patients with mandible fractures to receive a single dose of 30 mg ketorolac or placebo in the postanesthesia unit at the onset of pain. There was a significant reduction in analgesic requirements but no difference in pain intensity at any time points.

### Quantitative synthesis

Quantitative synthesis was not possible for any of the outcomes due to either a lack of two or more studies and inconsistent outcome definitions with respect to the timing of pain and methods to measure pain.

### PICO 2 recommendation

We conditionally recommend ketorolac be used in analgesic regimens for adult patients ( $\geq 18$  years old) with traumatic fracture. Ketorolac is associated with reduced opioid use and improved postoperative analgesia and is not associated with non-union. Five authors voted for a strong recommendation and 14 authors voted for conditional recommendation.

### PICO 3

Should selective NSAIDs (COX-2 inhibitors) be used in analgesic regimens for adult patients ( $\geq 18$  years old) with traumatic fracture versus routine analgesic regimens that include non-selective NSAIDs to improve analgesia and reduce OMEs, without increasing non-union rates?

### Non-union

#### Qualitative synthesis

Jeffcoach *et al*<sup>19</sup> report on a retrospective cohort study in patients with femur, tibia and/or humerus fractures at an academic level I trauma center. Non-union was not defined. In patients who received an NSAID (12%), most received a non-selective NSAIDs (93% ketorolac or ibuprofen, median of two doses) and seven patients (4%) experienced non-union. Only nine patients received a selective NSAID and none experienced a non-union (table 6). George *et al*<sup>4</sup> used private health insurance claims during a 15-year period in patients with a long-bone fracture and 1-year of follow-up data. In the 2411 patients receiving a COX-2 inhibitor, 69 (2.9%) experienced non-union compared with 387 (1.7%)—22 590 patients—receiving a non-selective NSAID. The incidence for non-union in this cohort was similar to the rate of non-union (1.5%) in patients not receiving NSAIDs.

Ortiz *et al*<sup>10</sup> randomized patients with closed ankles fractures to receive ketorolac (non-selective), diclofenac (non-selective) or etoricoxib (selective). There was no difference in the visual analog pain scores for any of the NSAIDs.

#### Quantitative synthesis

Due to the lack of studies, a meta-analysis was unable to be performed.

### PICO 3 recommendation

We are unable to make a recommendation on whether selective NSAIDs (COX-2 inhibitors) versus non-selective NSAIDs be used in analgesic regimens for adult patients ( $\geq 18$  years old) with traumatic fracture, due to the small number of studies identified. Four authors voted for a strong recommendation, two for conditional recommendation and 13 for no recommendation.

### USING THESE GUIDELINES IN CLINICAL PRACTICE

NSAIDs have a long history of use for analgesia in diseases with correctable and temporary causes of pain.<sup>27</sup> Traumatic fractures are extremely common and fall into this category, but concerns related to the impact of NSAIDs on bone healing have been raised in animal studies.<sup>29</sup> We aimed to address this question in addition to assessing the benefits of NSAIDs

**Table 6** PICO 3 (selective vs non-selective NSAIDs)

Author	Outcome definition	Groups	N	Male, n (%)	Age, years, mean (SD)	Outcome, n (%)	Study conclusions
<b>Non-union</b>							
Jeffcoach <sup>19</sup>	Not defined	Selective NSAID	8	NR	NR	0 (0)	No statement on selective NSAID use.
		Non-Selective NSAID	185	NR	NR	7 (3.8)	
George <sup>4</sup>	Non-union diagnosis code or a procedure to treat non-union	Selective NSAID	2 411	11 229 (45)	49 (17)	69 (2.9)	Filling a prescription for a non-selective NSAID after fracture was not associated with an increased risk of non-union in the subsequent year. Both COX-2-inhibitor and opioid prescription fills after fracture were associated with a greater risk of non-union.
		Non-Selective NSAID	22 590	103 003 (37)	60 (19)	387 (1.7)	
<b>Pain</b>							
Ortiz <sup>10</sup>	Pain (VAS) at 24 hours	Ketorolac (non-selective)	15	NA	39 (14)	25 (24 hours)	All studied NSAIDs were equally effective analgesics.
		Diclofenac (non-selective)	17	NA	38 (19)	25 (24 hours)	
		Etoricoxib (Selective)	17	NA	37 (10)	25 (24 hours)	

NSAID, non-steroidal anti-inflammatory drugs; VAS, visual analog scale.

## NSAIDS compared to No NSAIDS for orthopedic trauma

Patient or population: orthopedic trauma

Setting: inpatient

Intervention: NSAIDS

Comparison: No NSAIDS

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with No NSAIDS	Risk with NSAIDS				
Nonunion	22 per 1,000	<b>31 per 1,000</b> (23 to 43)	<b>OR 1.45</b> (1.04 to 2.01)	633389 (6 observational studies)	⊕○○○ Very low	Almost all studies retrospective and significant heterogeneity. Large studies dominates effect and demonstrates similar associations of opioids and anti-convulsants with nonunion.
Opioid Use	See Comment	mean <b>56 OME fewer</b> (87.87 fewer to 24.13 fewer)	-	190388 (5 RCTs)	⊕⊕⊕⊕ High	Three randomized control trials and two retrospective cohort trials. All studies demonstrated a decrease in post-traumatic fracture opioid use when NSAIDs were prescribed.
Analgesia	See Comment	not pooled	-	748 (7 RCTs)	⊕⊕⊕⊕ High	Six randomized control trials and two retrospective cohort trials. All but one study demonstrated a decrease in post-traumatic fracture pain use when NSAIDs were prescribed.

\*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio

### GRADE Working Group grades of evidence

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Figure 4 GRADEPro summary of findings.

with respect to acute pain control and need for opioids in trauma patients. Through our literature review, we conditionally recommend NSAIDs to reduce acute pain and opioid use due to traumatic fractures, [figure 4](#). The absolute difference between non-union in patients who receive or who do not receive NSAIDs in our analysis is <1%. This very small difference is outweighed by the reduction in opioids and improved analgesia. Some studies on longer duration NSAIDs (>30 days) demonstrated an association with non-union, but it remains unclear whether these patients had painful non-healing fractures requiring additional analgesic or that the NSAIDs lead to painful non-healing. Causality is impossible to determine from the current literature. Similar reviews on NSAIDs after orthopedic surgery have demonstrated the safety of NSAIDs for shorter durations (<2 weeks) and have identified indomethacin as particularly harmful.<sup>32</sup>

There was limited evidence available for more narrow questions of specific NSAIDs such as ketorolac or classes of NSAIDs: selective or non-selective. Ketorolac has a clear impact on pain and opioid reduction after traumatic fracture but only a single study<sup>14</sup> specifically commented on non-union (no difference). Again, the potential benefits of ketorolac

seem to outweigh any risk of non-union. Similarly, few studies compared selective and non-selective NSAIDs, and therefore no recommendations could be made. Further study is needed specifically regarding classification of NSAIDs and duration of NSAID use after traumatic fracture. Additionally, dosing regimens for NSAID can be examined for deleterious effects such as non-union. The ceiling analgesic dose may often be lower than that prescribed in practice, and this should be used to prescribe the smallest dose to achieve the desired effect.<sup>33,34</sup>

There are number of limitations to our systematic review and meta-analysis. The first is the inherent bias in designs of included studies. A number of the included studies were retrospective. The largest contributors of patients were large retrospective cohort studies of administrative database that may suffer from coding errors, missing data and selection bias.<sup>5,12,18</sup> Administrative studies also rely on prescription data and are unable to confirm compliance to NSAID regimen. Second, the definition of non-union was inconsistent between studies ranging from no definition in some studies to administrative coding or persistent fracture at 6 months in others. The third is the variability in the fracture type, presence of additional injuries (including additional fractures), indication

for NSAID and type and duration of NSAID. Specifically, the analgesic ceiling dose of NSAID has been established as much lower than the dose in most studies.<sup>33,34</sup> The higher dose given may contribute to the adverse events. Furthermore, some adverse events, such as gastrointestinal bleeding, were not identified as critically important. Finally, the heterogeneity of included studies does require consideration, particularly for the outcome of non-union ( $I^2=94\%$ ). Our PICO questions were defined a priori and took a clinical lens on the safety and efficacy of NSAIDs for patients suffering from traumatic fracture(s) rather than specific fracture types, thus a subgroup analysis was not performed. Future work is needed to determine whether certain fracture locations or patterns warrant special consideration.

## CONCLUSIONS

Based on the available evidence, non-steroidal anti-inflammatories have a clear effect on reducing post-traumatic fracture opioid use and improving pain control. These benefits outweigh the small risk of non-union.

## Author affiliations

<sup>1</sup>Department of Surgery, Division of Trauma and Acute Care Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

<sup>2</sup>Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA

<sup>3</sup>Department of Surgery, Johns Hopkins Univ, Baltimore, Maryland, USA

<sup>4</sup>Department of Orthopaedic Surgery, Washington University in St Louis, St Louis, Missouri, USA

<sup>5</sup>Department of Surgery, McGill University, Montreal, Québec, Canada

<sup>6</sup>Holy Spirit Hospital Penn State Health, Camp Hill, Pennsylvania, USA

<sup>7</sup>Department of Orthopaedics, University of Utah Health, Salt Lake City, Utah, USA

<sup>8</sup>Department of Orthopaedic Surgery, Henry Ford Hospital, Detroit, Michigan, USA

<sup>9</sup>Department of Orthopaedic Surgery, University of South Florida, Tampa, Florida, USA

<sup>10</sup>Department of Surgery, Duke University, Durham, North Carolina, USA

<sup>11</sup>The Vanderbilt Orthopaedic Institute Center for Health Policy, Nashville, Tennessee, USA

<sup>12</sup>Department of Orthopaedic Surgery, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA

<sup>13</sup>Institute Center for Health Policy, Nashville, Tennessee, USA

<sup>14</sup>Department of Surgery, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

<sup>15</sup>Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, New York, USA

<sup>16</sup>Department of Surgery, TCU and UNTHSC School of Medicine, Fort Worth, Texas, USA

<sup>17</sup>Department of Surgery, University of Florida College of Medicine – Jacksonville, Jacksonville, Florida, USA

<sup>18</sup>Department of General Surgery, Sunrise Hospital and Medical Center, Las Vegas, Nevada, USA

**Contributors** All authors contributed to the screening of articles, full-text review, data extraction and critical review of the article. PBM performed the meta-analysis. All authors voted on outcomes. PBM is responsible for the overall content and guarantor.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** ERH reports research funding from The Patient-Centered Outcomes Research Institute, the Agency for Healthcare Research and Quality, the National Institutes of Health/National Heart, Lung, and Blood Institute, the Department of Defense/Army Medical Research Acquisition Activity and the Henry M. Jackson Foundation for the Advancement of Military Medicine. ERH is a volunteer past president of the Eastern Association for the Surgery of Trauma (EAST) and past chair of the EAST guidelines committee.

**Patient consent for publication** Not applicable.

**Ethics approval** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iDs

Patrick B Murphy <http://orcid.org/0000-0002-6086-8966>

George Kasotakis <http://orcid.org/0000-0002-7630-0742>

Elliott R Haut <http://orcid.org/0000-0001-7075-771X>

Jennifer J Freeman <http://orcid.org/0000-0001-9144-2645>

## REFERENCES

- Stoicescu N, Costa A, Periel L, Uribe A, Weaver T, Bergese SD. Current perspectives on the opioid crisis in the US healthcare system: a comprehensive literature review. *Medicine (Baltimore)* 2019;98:e15425.
- Rudd RA, Seth P, David F, Scholl L. Morbidity and mortality weekly report. *MMWR Surveillance Summaries* 2021;70:293.
- Aliuskevicius M, Østgaard SE, Vestergaard P, Rasmussen S. The influence of ibuprofen on the healing of nonsurgically treated Colles' fractures. *Orthopedics* 2021;44:105–10.
- George MD, Baker JF, Leonard CE, Mehta S, Miano TA, Hennessy S. Risk of nonunion with nonselective NSAIDs, COX-2 inhibitors, and opioids. *J Bone Joint Surg Am* 2020;102:1230–8.
- Haines KL, Fuller M, Vaughan JG, Krishnamoorthy V, Raghunathan K, Kasotakis G, Agarwal S, Ohnuma T. The impact of nonsteroidal anti-inflammatory drugs on older adult trauma patients with hip fractures. *J Surg Res* 2020;255:583–93.
- Tucker WA, Birt MC, Heddings AA, Horton GA. The effect of postoperative nonsteroidal anti-inflammatory drugs on nonunion rates in long bone fractures. *Orthopedics* 2020;43:221–7.
- Xu W, Zhang N, Ni M, Wang B, Fang H. The comparative study on the combination of ketorolac tromethamine and sufentanil for postoperative analgesia in patients receiving traumatic lower limb surgery: a randomized controlled trial. *Int J Clin Exp Med* 2016;9:2969–76.
- Eftekharian HR, Ilkhani Pak H. Effect of intravenous ketorolac on postoperative pain in mandibular fracture surgery; a randomized, double-blind, placebo-controlled trial. *Bull Emerg Trauma* 2017;5:13–7.
- Bayouth L, Safcsak K, Cheatham ML, Smith CP, Birrer KL, Promes JT. Early intravenous ibuprofen decreases narcotic requirement and length of stay after traumatic rib fracture. *Am Surg* 2013;79:1207–12.
- Ortiz Mlet al. Effectiveness of diclofenac, ketorolac and etoricoxib in the treatment of acute pain from ankle fracture. *Proc West Pharmacol Soc* 2014;53:46–8.
- Zhang C, Zhou X. Effectiveness of various non-steroidal anti-inflammatory drugs in pain management of patients with vertebral fracture: a comparative clinical study. *Trop J Pharm Res* 2017;16:2275.
- Zura R, Xiong Z, Einhorn T, Watson JT, Ostrum RF, Prayson MJ, Della Rocca GJ, Mehta S, McKinley T, Wang Z, et al. Epidemiology of fracture nonunion in 18 human bones. *JAMA Surg* 2016;151:e162775:1–12.
- Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. *J Bone Joint Surg Br* 2003;85:700–5.
- McDonald EL, Daniel JN, Rogero RG, Shakked RJ, Nicholson K, Pedowitz DI, Raikin SM, Bilolikar V, Winters BS. How does perioperative ketorolac affect opioid consumption and pain management after ankle fracture surgery? *Clin Orthop Relat Res* 2020;478:144–51.
- Sagi HC, Jordan CJ, Barei DP, Serrano-Riera R, Steverson B. Indomethacin prophylaxis for heterotopic ossification after acetabular fracture surgery increases the risk for nonunion of the posterior wall. *J Orthop Trauma* 2014;28:377–83.
- Weisz RD, Fokin AA, Lerner V, Flynt A, Macias-Perez I, Pavliv L, Crawford M, Puente I. Intravenous ibuprofen reduces opioid consumption during the initial 48 hours after injury in orthopedic trauma patients. *J Orthop Trauma* 2020;34:341–7.
- Adolphson P, Abbaszadegan H, Jonsson U, Dalén N, Sjöberg HE, Kalén S. No effects of piroxicam on osteopenia and recovery after Colles' fracture. A randomized, double-blind, placebo-controlled, prospective trial. *Arch Orthop Trauma Surg* 1993;112:127–30.

- 18 Buchheit T, Zura R, Wang Z, Mehta S, Della Rocca GJ, Steen RG. Opioid exposure is associated with nonunion risk in a traumatically injured population: an inception cohort study. *Injury* 2018;49:1266–71.
- 19 Jeffcoach DR, Sams VG, Lawson CM, Enderson BL, Smith ST, Kline H, Barlow PB, Wylie DR, Krumenacker LA, McMillen JC, *et al.* Nonsteroidal anti-inflammatory drugs' impact on nonunion and infection rates in long-bone fractures. *J Trauma Acute Care Surg* 2014;76:779–83.
- 20 Godoy Monzón D, Vazquez J, Jauregui JR, Iserson KV. Pain treatment in post-traumatic hip fracture in the elderly: regional block vs. systemic non-steroidal analgesics. *Int J Emerg Med* 2010;3:321–5.
- 21 Moed BR, Karges DE. Prophylactic indomethacin for the prevention of heterotopic ossification after acetabular fracture surgery in high-risk patients. *Journal of Orthopaedic Trauma* 1994;8:34–9.
- 22 Hunter AM, Montgomery TP, Pitts CC, Moraes L, Anderson M, Wilson J, McGwin G, Shah A. Postoperative aspirin use and its effect on bone healing in the treatment of ankle fractures. *Injury* 2020;51:554–8.
- 23 Mehta SD. A randomized double-blind placebo-controlled study of dipyron and aspirin in post-operative orthopaedic patients. *J Int Med Res* 1986;14:63–6.
- 24 Marquez-Lara A, Hutchinson ID, Nuñez F, Smith TL, Miller AN. Nonsteroidal anti-inflammatory drugs and bone-healing: a systematic review of research quality. *JBJS Rev* 2016;4:e4:1–14.
- 25 Borgeat A, Ofner C, Saporito A, Farshad M, Aguirre J. The effect of nonsteroidal anti-inflammatory drugs on bone healing in humans: a qualitative, systematic review. *J Clin Anesth* 2018;49:92–100.
- 26 Wheatley BM, Nappo KE, Christensen DL, Holman AM, Brooks DI, Potter BK. Effect of NSAIDs on bone healing rates: a meta-analysis. *J Am Acad Orthop Surg* 2019;27:e330–6.
- 27 Hsu JR, Mir H, Wally MK, Seymour RB, Orthopaedic Trauma Association Musculoskeletal Pain Task Force. Clinical practice guidelines for pain management in acute musculoskeletal injury. *J Orthop Trauma* 2019;33:e158–82.
- 28 AAOS. Pharmacologic, physical, and cognitive pain alleviation for musculoskeletal extremity/pelvis surgery. 2021
- 29 Guyatt GH, Gunn V, Yngve F-Y, *et al.* Grade: an emerging consensus on rating quality of evidence and strength of recommendations. *Chin J Evid Based Med* 2009;9:8–11.
- 30 Haut ER. Eastern association for the surgery of trauma (East) practice management guidelines and the perpetual quest for excellence. *J Trauma Acute Care Surg* 2020;89:1–10.
- 31 Kerwin AJ, Haut ER, Burns JB, Como JJ, Haider A, Stassen N, Dahm P, Eastern Association for the Surgery of Trauma Practice Management Guidelines Ad Hoc Committee. The eastern association of the surgery of trauma approach to practice management Guideline development using grading of recommendations, assessment, development, and evaluation (grade) methodology. *J Trauma Acute Care Surg* 2012;73:S283–7.
- 32 Al Farii H, Farahdel L, Frazer A, Salimi A, Bernstein M. The effect of nsais on postfracture bone healing: a meta-analysis of randomized controlled trials. *OTA Int* 2021;4.
- 33 Motov S, Yasavolian M, Likourezos A, Pushkar I, Hossain R, Drapkin J, Cohen V, Filk N, Smith A, Huang F, *et al.* Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. *Ann Emerg Med* 2017;70:177–84.
- 34 Motov S, Masoudi A, Drapkin J, Sotomayor C, Kim S, Butt M, Likourezos A, Fassassi C, Hossain R, Brady J, *et al.* Comparison of oral ibuprofen at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. *Ann Emerg Med* 2019;74:530–7.